| HS Code | 252613 |
| Product Name | Interferon Veterinary Grade API |
| Product Category | Active Pharmaceutical Ingredient |
| Available Dosage Forms | Tablets, Injections, Capsules, Powders, Granules, Premix, Solutions |
| Veterinary Species | Cattle, Swine, Poultry, Dogs, Cats |
| Pharmacological Class | Immunomodulator |
| Mechanism Of Action | Binds to interferon receptors to induce antiviral, antiproliferative, and immunomodulatory responses |
| Indications | Treatment and prevention of viral infections and immune deficiency in animals |
| Physical Form | Lyophilized powder or sterile solution |
| Solubility | Soluble in water and physiological buffers |
| Purity | Greater than or equal to 98% |
| Storage Conditions | Store at 2-8°C, protected from light and moisture |
| Shelf Life | 24 months from date of manufacture |
| Quality Standard | Veterinary Grade / GMP compliant |
| Excipient Compatibility | Compatible with common tablet, capsule, powder, granule, premix, and solution excipients |
As an accredited Interferon Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Interferon Veterinary Grade API is supplied in sealed, moisture-resistant drums with tamper-evident closures. Quantity: 1 kg per drum. |
| Container Loading (20′ FCL) | 20′ FCL container loading of veterinary-grade Interferon API in tablets, injections, capsules, powders, granules, premix, and solutions, with secure, compliant handling. |
| Shipping | Shipment of Interferon Veterinary Grade API requires strict cold-chain handling (2–8°C) to preserve potency. Packed in sealed, inert containers with desiccants and temperature loggers. International transport via expedited air freight, following IATA/ADR regulations. Full documentation includes Certificate of Analysis, MSDS, and cold-chain compliance records. |
| Storage | Store tightly sealed in the original container, protected from light and moisture. Recommended storage: 2–8°C (refrigerated); do not freeze. Avoid temperature excursions and prolonged exposure to air. Keep in a dry, well-ventilated area, away from incompatible substances. Follow label instructions and local veterinary regulations for handling and disposal. |
| Shelf Life | Shelf life: 24 months when stored at 2–8°C, protected from light, in unopened original packaging. |
Veterinary interferon alpha formulations intended for sterile injection are processed as lyophilized plugs in Type I glass vials after aseptic filling. The bulk solution typically contains 5 mM to 20 mM histidine or phosphate buffer, 20 mg/mL to 50 mg/mL mannitol or 40 mg/mL trehalose dihydrate, 0.01% w/v to 0.05% w/v polysorbate 20, and 0.1 mM to 1.0 mM disodium edetate. The sugar-to-protein mass ratio is held between 1:1 and 5:1 so the amorphous cake remains above its critical glass transition during primary drying. Sterile filtration passes the solution through a 0.22 μm polyvinylidene fluoride membrane preceded by a 0.45 μm bioburden membrane under nitrogen pressure of 0.2 MPa to 0.3 MPa. Filling is executed in an ISO 14644-1 Class 5 environment inside a restricted-access barrier system. The lyophilization cycle is designed so product temperature remains below the collapse temperature, commonly between -25°C and -28°C during sublimation, while the shelf is ramped from -45°C freezing to 25°C to 35°C secondary drying. Chamber pressure is controlled at 50 mTorr to 200 mTorr during primary drying, and Karl Fischer moisture after stopper closure is required to remain below 3.0% w/w under USP <921> or equivalent. A collapsed or meltback cake raises reconstitution time and residual moisture. On a 20 m² production lyophilizer, edge vials frequently show higher moisture than center vials because of radiative heat transfer from chamber walls; this is corrected by manometric temperature measurement and shelf power modulation rather than by extending the secondary drying hold alone. Sterility release follows Ph. Eur. 2.6.1, and batch consistency for biological activity is evaluated against a reference standard expressed in IU/mg under VICH GL18.
| Stage | Equipment setpoint | Control method | Typical production-scale failure |
|---|---|---|---|
| Freezing | shelf ramp to -45°C, hold 3 h | product thermocouple verification | incomplete ice nucleation and vial breakage |
| Primary drying | shelf -25°C to -20°C, chamber 50 mTorr to 150 mTorr | Pirani vs capacitance manometer pressure comparison | cake collapse at edge rows |
| Secondary drying | shelf 25°C to 35°C, hold 6 h to 12 h | Karl Fischer USP <921> | residual moisture overshoot above 3.0% w/w |
For orally administered interferon powders supplied in aluminum foil sachets, the lyophilized or spray-dried drug substance is blended with 2.0 wt% to 5.0 wt% colloidal silicon dioxide and 10 wt% to 30 wt% mannitol to produce a free-flowing mixture. The residual moisture specification after vacuum drying at 25°C for 24 h is set at 1.5% w/w to 2.5% w/w because higher moisture plasticizes the amorphous protein-excipient matrix and shifts the glass transition below 40°C, causing caking under tropical storage conditions. Reconstitution is performed with potable water or an oral syringe; the powder should wet within 60 s under gentle swirling, and the pH of the reconstituted suspension is held at 6.0 to 7.0 with a 10 mM citrate or phosphate system to reduce deamidation. The finished powder is filled by auger filler into low-moisture-barrier laminate sachets with an oxygen transmission rate below 0.1 cm³/m²/day and a water vapor transmission rate below 0.05 g/m²/day at 38°C/90% RH. Filling accuracy is controlled with 100% checkweighing to ±3% of target weight. Published data for specific activity recovery after 8 weeks at 30°C/75% RH in this exact sachet configuration is limited; ongoing stability is therefore bracketed by a reduced stability protocol rather than assumed from liquid dosage forms.
Fluid-bed top spray granulation of veterinary interferon granules requires a 25 kg to 50 kg batch in a top-spray fluid-bed processor with inlet air dew point below -20°C. A 10% w/v hydroxypropyl methylcellulose E5 binder solution is sprayed at 5 g/min to 10 g/min onto 150 μm to 250 μm mannitol-lactose seeds. Inlet air temperature is held at 35°C to 45°C, product temperature at 28°C to 32°C, and exhaust relative humidity below 12%. The granulation endpoint is determined by moisture content of 1.5% w/w to 2.0% w/w and particle size distribution with d50 between 250 μm and 500 μm. Oversized granules above 900 μm are passed through a 1.0 mm conical mill at 600 rpm, and fines below 90 μm are recycled to the next batch or removed to prevent loss-on-drying drift. The dried granules are mixed with 0.5% w/w magnesium stearate and 1.0% w/w sodium starch glycolate for 2 min in a V-blender at 25 rpm; extended mixing above 5 min is avoided because shear-induced surface energy can reduce compressibility and increase yield pressure from 180 MPa to 220 MPa. Acceptance is based on Hausner ratio below 1.25 and Carr index below 20%, with disintegration of the final tablet or capsule form checked by Ph. Eur. 2.9.1 or USP <701>.
Compressed veterinary interferon tablets intended for feline or canine oral mucosal absorption are handicapped by gastric acid and pepsin degradation, so the formulation uses a granulated core that is first protected by an enteric subcoat before any mucoadhesive strategy is considered. The core contains 2.0% w/w interferon premix, 55% w/w dibasic calcium phosphate dihydrate, 20% w/w microcrystalline cellulose, 10% w/w crospovidone, 4% w/w hydroxypropyl methylcellulose E5, 2% w/w colloidal silicon dioxide, and 1% w/w sodium stearyl fumarate. Compression is performed on a rotary press with 10 kN to 18 kN main compression force and 4 kN to 6 kN precompression, targeting tablet hardness of 40 N to 70 N. The subcoat uses a 2.5% w/w methacrylic acid copolymer type C dispersion applied at 5 mg/cm² to 8 mg/cm² weight gain in a side-vented pan at inlet air 45°C to 50°C, spray rate 10 g/min, and atomizing pressure 0.8 bar. After coating, the tablets pass a two-hour acid resistance test in 0.1 N hydrochloric acid at 37°C with no more than 10% of label claim released, followed by phosphate buffer pH 6.8 with not less than 75% released in 45 min according to USP <711>. Because interferon is a protein, enteric protection alone does not address insufficient buccal contact time; a separate mucoadhesive bilayer or an orodispersible carrier may be required, and published data for this specific veterinary tablet geometry is limited.
Hydroxypropyl methylcellulose capsule fill containing veterinary interferon is pre-conditioned to 25°C/35% RH for 24 h prior to filling because HPMC shells become brittle below 10% w/w water and soften above 18% w/w water. A dosator-type capsule filler operating at 30,000 capsules/hour is used with fill weight 180 mg to 220 mg and fill plug height adjusted to 8 mm to 10 mm. The powder blend consists of 5% w/w interferon milled premix, 45% w/w mannitol, 45% w/w microcrystalline cellulose, 3% w/w croscarmellose sodium, and 1% w/w fumed silica, with 0.5% w/w magnesium stearate added after dry blending. The blend is sealed into size 3 HPMC capsules and then enteric coated with a methacrylic acid copolymer type C dispersion to a weight gain of 7% to 10% w/w; dissolution acceptance is based on USP <711> two-stage testing. Acid exposure can reduce specific activity, so an acid-neutralizing buffer granule is not included unless the shell is enteric-coated. The finished capsules are packaged in aluminum-aluminum blisters with desiccant and released for veterinary oral use only after 100% visual inspection for shell cracking.
A veterinary interferon premix for incorporation into swine or poultry starter feed is only technically defensible when the carrier and release mechanism are designed for dry heat stress and pepsin exposure. The premix base uses 80% w/w ground rice hulls or corncob meal with particle size 200 μm to 500 μm and 15% w/w soy lecithin as a dust binder, onto which a 5% w/w protected interferon concentrate is adsorbed in a ribbon mixer at 20 rpm for 8 min. Uniformity is tested by taking 20 samples from different points and assaying with a protein-specific ELISA; acceptance is 95% to 105% of label claim and relative standard deviation below 5%. When the premix is diluted into complete feed at 1 kg/ton to 10 kg/ton, segregation occurs if the carrier density differs by more than 0.2 g/cm³ from the feed base. The carrier density is therefore specified at 0.45 g/cm³ to 0.55 g/cm³, and the final feed is mixed in a horizontal batch mixer for no less than 3 min after premix addition. The medicated feed is not pelleted above 65°C because interferon loses activity rapidly above this threshold unless protected by a lipid or methacrylate barrier; published data for this specific protected premix in pelleted feed is limited. The premix is assigned an expiration period only after 6-month stability in HDPE-lined multiwall bags at 25°C/60% RH.
Ready-to-use oral solutions of veterinary interferon are formulated as clear aqueous vehicles with 50% w/w sorbitol or glycerol to increase viscosity and reduce swallowing loss, 0.05% w/w methylparaben and 0.01% w/w propylparaben as preservative, and 10 mM sodium acetate buffer at pH 5.0 to 6.0 to stabilize the protein. The solution is filled into amber PET bottles fitted with a polyethylene dropper or a calibrated oral dosing syringe; product temperature during holding is maintained at 2°C to 8°C, and the solution is not subjected to terminal heating because interferon denatures at 60°C to 70°C. Fill volume is controlled to ±1% by peristaltic pump with in-line checkweigher. Because liquid water increases deamidation and oxidation, a nitrogen headspace blanket is applied to reduce dissolved oxygen below 1.0 mg/L, and the closure is torqued to 1.2 N·m to 1.5 N·m to minimize gas ingress. Released product is tested for pH, preservative assay, and visual clarity per Ph. Eur. 2.2.2 or USP <791>.
Competitive Interferon Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
For manufacturers of veterinary finished dosage forms, Interferon Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a purified recombinant protein powder or lyophilized cake for further processing. The product line is assigned the model codes IFN-V-α-0201-LYO, a lyophilized injection grade, and IFN-V-α-0201-SD, a spray-dried oral dosage grade. Both grades are produced by recombinant expression, captured by chromatographic steps, and polished by ion-exchange and size-exclusion chromatography. The API is not a finished veterinary medicinal product, is not sterile in oral grades, and is not intended for direct administration. The lyophilized grade is formulated for reconstitution into injectable solutions and for dry blending into tablets and capsules; the spray-dried grade is engineered for low-dust premix and granule manufacture with controlled bulk density and particle-size distribution. Release documentation includes identity by immunoblot, potency by antiviral cytopathic-effect inhibition assay, purity by SDS-PAGE, endotoxin by limulus amebocyte lysate test, residual host-cell protein by ELISA, residual host-cell DNA by qPCR, and water content by Karl Fischer titration.
Injectable-grade material is controlled to the acceptance criteria in Table 1. Potency is assigned by a cytopathic-effect inhibition assay using MDBK cells challenged with vesicular stomatitis virus and calibrated against the appropriate interferon reference standard. Monomer content is determined by SDS-PAGE under reducing and non-reducing conditions. Endotoxin is controlled by Ph. Eur. 2.6.14 because an injectable API with elevated endotoxin cannot be detoxified by terminal sterilization; the limit is derived from the intended dose and route of administration. Sterility is evaluated by Ph. Eur. 2.6.1 for material labeled sterile. The oral grade is not required to be sterile, but bioburden is controlled to ≤ 10 CFU/g by Ph. Eur. 2.6.12. Water content is limited to reduce hydrolytic degradation during storage. Residual host-cell protein is controlled to ≤ 100 ng/mg in both grades; residual DNA is controlled to ≤ 10 ng/dose for injectable application.
| Parameter | Method | Lyophilized injection grade | Spray-dried oral grade |
|---|---|---|---|
| Potency | CPE inhibition, MDBK/VSV | ≥ 1.0 × 10^8 IU/mg | ≥ 5.0 × 10^7 IU/mg |
| Purity by SDS-PAGE | Reducing and non-reducing | ≥ 95.0% monomer | ≥ 90.0% monomer |
| Endotoxin | Ph. Eur. 2.6.14 | ≤ 0.25 EU/µg | Not applicable |
| Bioburden | Ph. Eur. 2.6.12 | ≤ 10 CFU/g unless sterile | ≤ 10 CFU/g |
| Sterility | Ph. Eur. 2.6.1 | No growth where sterile grade is specified | Not tested for non-sterile grade |
| Water content | Ph. Eur. 2.5.32 | ≤ 3.0% w/w | ≤ 5.0% w/w |
| Residual host-cell protein | ELISA | ≤ 100 ng/mg | ≤ 100 ng/mg |
| Residual host-cell DNA | qPCR | ≤ 10 ng/dose | ≤ 10 ng/mg |
The particle-size distribution of the spray-dried grade is controlled by laser diffraction to improve blend uniformity in low-dose premixes. The target D90 is ≤ 150 µm for direct compression and ≤ 250 µm for premix dilution. Bulk density is 0.2–0.5 g/cm³, and tapped density is used to calculate Hausner ratio; a Hausner ratio of 1.00–1.30 indicates acceptable flow for rotary tablet press feed frames. Values above 1.45 indicate cohesive flow and require addition of glidant such as colloidal silicon dioxide at 0.5–2.0% w/w. Sieve analysis after dry blending confirms that the API does not demix from coarse carriers; the mass fraction retained on a 500 µm sieve is ≤ 5.0% unless the carrier specification requires otherwise.
Dry blending and direct compression are preferred for oral solids because aqueous granulation introduces shear, heat, and moisture that can promote aggregation and loss of antiviral activity. The spray-dried grade is mixed with lactose monohydrate, microcrystalline cellulose, or corncob meal in a bin blender or V-blender. Blend uniformity is evaluated according to Ph. Eur. 2.9.40; the acceptance value for single-dose tablets should not exceed 15. If wet granulation is unavoidable, a high-shear granulator with jacketed cooling or a twin-screw granulator with cooled barrels is used, and the granulation liquid is maintained below 10°C before addition. The wet mass is dried in a fluid-bed dryer with inlet air temperature not exceeding 35°C; product temperature is monitored continuously and the drying end-point is set by loss-on-drying to ≤ 2.0% w/w for tablet granules and ≤ 5.0% w/w for premix granules. These thermal boundaries reflect the general heat lability of type I interferons; published data for this specific API formulation is limited and should be confirmed by forced-degradation studies under ICH Q5C and VICH GL3(R) conditions.
In feed-mill and veterinary compounding operations, the spray-dried API is diluted stepwise in a ribbon mixer or planetary mixer before final premix packaging. Because the target dose can vary from 0.1 × 10^6 IU/kg body weight for companion animals to 1.0 × 10^6 IU/kg for production animals, geometric dilution is used to prevent segregation. The first dilution is 1:10 API to carrier; the second 1:10 is mixed for 15–20 min at 20–40 rpm. The final premix is sampled from 10 locations and assayed by ELISA or CPE inhibition to verify that the concentration is within ± 10% of the labeled value. This stepwise dilution protocol reduces the risk of segregation in low-dose premixes but is only a general operating range; site-specific mixing studies are required because published data for this specific configuration is limited.
For injectable solutions, the lyophilized cake is reconstituted in a buffered vehicle containing a stabilizer such as trehalose or mannitol. The target protein concentration is typically 1.0–10.0 mg/mL. The solution is filtered through a 0.45 µm prefilter and then a 0.22 µm sterilizing-grade membrane. PES and PVDF membranes are used because regenerated cellulose and nylon can bind protein and reduce yield; filterability is assessed by measuring normalized filtration volume before flux decay. Terminal autoclaving at 121°C for 15 min is incompatible with the API; aseptic processing is therefore required for sterile injectable presentations. Filling of vials or prefilled syringes is conducted under Grade A air with Grade B background. Silicone oil in prefilled syringe glass barrels may induce protein aggregation; if silicone oil is present, a shaking stress study is performed to compare subvisible particles.
Reconstitution time is tested by adding 1.0 mL water for injection to the lyophilized cake and agitating gently; complete dissolution should occur in ≤ 3 min at 20–25°C. The reconstituted solution is examined for subvisible particles by light obscuration according to Ph. Eur. 2.9.19; the acceptance criterion is ≤ 6000 particles per container at ≥ 10 µm and ≤ 600 particles per container at ≥ 25 µm for small-volume parenterals. These are compendial thresholds for injectable preparations, not API-specific safety limits. Endotoxin and sterility are repeated on the finished injectable solution because aseptic processing can introduce contamination not detected in bulk powder.
Stress studies for tablets and capsules use temperature and humidity conditions defined in ICH Q1A(R2) and VICH GL3(R). For proteinaceous APIs, short exposure periods of 7–14 days at 25°C/60% RH and 40°C/75% RH are used to detect aggregation. Potency is measured by CPE inhibition at each time point; high-molecular-weight species are measured by size-exclusion HPLC with UV detection at 214 nm. Degradation is considered significant when monomer content falls below 90.0% or potency declines by more than 0.5 log10 relative to time zero. Tablets manufactured by direct compression should show hardness of 30–70 N and friability ≤ 1.0% according to Ph. Eur. 2.9.7 and Ph. Eur. 2.9.8; these values are formulation-dependent and are not API release criteria. Dissolution testing for oral powder or tablet formulations uses Ph. Eur. 2.9.3 apparatus II at 50 rpm with 900 mL of 0.1 M acetate buffer at pH 4.5; the acceptance is ≥ 75% dissolved in 45 min for immediate-release presentations. These thresholds are common for protein-containing solid oral dosage forms; product-specific limits are to be justified by batch data.
For oral solutions, the lyophilized API is dissolved in purified water containing a buffer, stabilizer, and preservative. The solution is clarified through a 0.45 µm membrane before filling into amber glass or high-density polyethylene bottles. Because interferon alpha adsorbs to borosilicate glass at low protein concentration, a bulk concentration of ≥ 0.5 mg/mL or a surface-active stabilizer is used. The finished solution is stored at 2–8°C; physical stability is evaluated by visual inspection, pH, and subvisible particle count. Oral powders are dry-mixed with sweetening agents and diluents, then filled into sachets under controlled humidity ≤ 40% RH to avoid powder caking. Granules for reconstitution follow the same drying boundaries as tablet granules; the dry granulation route with roller compaction is preferred over wet granulation when the formulation contains moisture-sensitive excipients.
The CPE inhibition assay has an inter-assay variability of ± 0.3 log10 when the same reference standard and MDBK/VSV challenge are used. To reduce variability, each plate includes a five-point standard curve and three quality control samples. The 50% endpoint is calculated by four-parameter logistic or Reed-Muench methods. Potency is reported in international units per milligram; if the 95% confidence interval of the sample potency overlaps the lower specification limit, the batch is retested. Use of a qualified international reference standard or an internal reference standard calibrated against it is mandatory. This assay variability is a recognized limitation of biological potency tests and is not specific to veterinary-grade interferon; it affects batch release timelines and requires statistical trending of potency data.
The API is incompatible with strong oxidizing agents, reducing agents, and prolonged exposure to alkaline pH. In tablet formulations, magnesium stearate at levels above 1.0% w/w may reduce dissolution by hydrophobic film formation, but this is an excipient interaction rather than API degradation. For premix carriers, zeolite and bentonite at high inclusion rates may adsorb the protein and reduce assay recovery; if these carriers are used, recovery should be verified by ELISA. These interactions are formulation-dependent and are to be evaluated in development. Terminal gamma irradiation of the final premix should not be used because ionizing radiation can fragment the protein backbone; if irradiation is required for bioburden control, the maximum absorbed dose should be justified by potency and purity data.
Interferon veterinary-grade API differs from small-molecule antiviral or immunomodulatory compounds in that it is a protein with defined primary, secondary, and tertiary structure, and its activity is measured in international units rather than mass units alone. Unlike synthetic small molecules, it cannot be autoclaved, requires cold-chain storage at 2–8°C in lyophilized form, and is sensitive to organic solvents, strong acids, strong bases, and high-shear processing. Compared with E. coli-derived recombinant human interferon alpha-2b, which is non-glycosylated, the veterinary-grade alpha-2 material may be produced in a eukaryotic host to introduce O-linked glycosylation at Thr-106; this post-translational modification influences solubility, aggregation resistance, and immunogenicity. Feline interferon omega products produced in baculovirus/silkworm systems are glycosylated type I interferons with species-specific receptor binding; they are not interchangeable with interferon alpha in all veterinary indications. The veterinary-grade API supplied for tablets, injections, capsules, powders, granules, premix, and solutions is differentiated by its bulk presentation, particle engineering, and release specification tailored to the target dosage form rather than by a finished-product brand name.
Operational boundaries apply to storage, reconstitution, and formulation. The lyophilized cake is stored at 2–8°C and protected from light; repeated freeze-thaw cycles of reconstituted solution are not recommended because aggregate formation may exceed 5.0% high-molecular-weight species. The spray-dried oral grade is stored at 2–8°C or ≤ 25°C only if stability data support it. The API should not be combined with benzyl alcohol in multi-dose injectable formulations unless compatibility is demonstrated by subvisible particle analysis and potency retention. Contact with silicone oil in prefilled syringes should be avoided unless the specific barrel coating is tested. Phosphate-buffered saline at concentrations above 50 mM may reduce solubility at low pH. These constraints are based on general protein formulation principles; product-specific forced-degradation and compatibility protocols are required before routine use.
